CG Oncology : Investor Presentation (Apr 14, 2026)

Published: 2026-04-14 12:06:13 ET CGON

Published on 04/14/2026 at 12:06 pm EDT

| 1

The Promise of Cretostimogene

Potential Best-in-Disease Durability and Efficacy

Potential Best-in-Disease Safety/Tolerability

Regulatory & Commercial Readiness

BOND-003 Cohort C (HR BCG UR

CIS only)1:

76% CR anytime

46.4% (12-mo)

41.8% (24-mo)

BOND-003 Cohort P (HR BCG UR

Ta/T1 Disease)2

95.7% (3-mo) HG-EFS

84.6% (6-mo)

80.4% (9-mo)

CORE-008 Cohort A (HR BCG Na"ive

CIS)2

Favorable safety & tolerable profile

0 Grade » 3 TRAEs or deaths

reported

Most AEs were Grade 1-2

Granted Breakthrough Therapy & Fast Track designations

Current capacity: 40-5Ok vials/year; 1Ox scale-up process to support future indications underway

Pre-launch activities ongoing -MSLs/HSDs, site / payor engagement

Administered like BCG, seamlessly integrating into established clinical workflows without re-training

Physicians in top key accounts treat

88% CR anytime (optimized instillation)

>7OOX» of NMIBC patients by volume

Dual MOA designed to selectively drive tumor killing & trigger durable anti-tumor immune response resulting in

potential for best-in-disease profile across a broad range of NMIBC patients

TRAEs = Treatment-related adverse events; HR = high-risk; NMIBC - Non-muscle invasive bladder cancer; MSL = Medical science liaison; HSD = Health system directors; MOA = Mechanism of action

1. Ph 3 registrational study in HR BCG-unresponsive NMIBC CIS 2. Data presented at SUO Annual Meeting Dec 2025, data as of September 1, 2025

1a 1b

Cancer Cell

Cretostimogene is lntravesically Administered into the Bladder, Similar to

Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly

Procedure Can Be

BCG - Bacillus Calmette Guerin. DDM = n-DodecyI β-D-maltoside. GAG = glycosaminoglycan.

-15 minutes

Standard

DDM

Cretostimogene Programs Across High-Risk & Intermediate-Risk NMIBC Address More Than 7OO/oof NMIBC Market Potential

85K+

Bladder Cancer (U.S. Incidence)

730K+

Bladder Cancer (U.S. Prevalence)

75 % NMIBC

High-Risk (40%)

PIVOT-006

Ph G Monotherapy

Cohort B

BCG-Na"ive

CORE-0081

Cohort A

CORE-0081

Cohort CX

BOND-003

Ph 3 Monotherapy Ph 2 Checkpoint

Cohort C/ Cohort P Combo

Note: CORE-001, CORE-008 Cohort B, and PIVOT-006 are in partnership with SUO-CTC. 1 CORE-008 is a multi-cohort study evaluating cretostimogene in High-Risk NMIBC.

*jCG 9

NMIBC = Non-muscle invasive bladder cancer OflCOtMY

▪ ▪ ▪

▪

o o

▪ ▪

▪

Cohort C

BOND-003

Cretostimogene Has Delivered Best-in-Disease Complete Response (CR) Rate at 24 Months

Complete Response (CR) at 24-Month

42%

(46/110)

25%

19%

(20/103)

Cretostimogene N-803 + BCG Nadofaragene Pembrolizumab

1. Compared to approved drugs with publicly available observed 24-Month CR data

Cretostimogene demonstrated best-in-disease long-term DoR compared to approved drugs1 in NMIBC with 41.8% of patients in CR at 24 months

90% of patients in CR at 1 2 months maintained in CR at 24 months

No grade 3+ TRAEs - best-in-disease safety and tolerability profile

CQ 12

Note: These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across @@

studies. From published data.

CIS with or without Ta/T1

Cretostimogene is Well Positioned as Backbone Therapy in

NMIBC with Best-in-Disease Durability & Safety in HR BCG-UR 1

Trial (Status)

Drug Mechanism

RoA

Efficacy Population CRatAnyTime

CR at 12 Mo CR at 24 Mo

12M DOR

24M DOR

Free from Progression

to MIBC

Cystectomy Free Survival Median Time to AE Resolution Grade 3+ TRAE

BOND-003 COHORT C

(Ph3 Ongoing)

Cretostimogene

Oncolytic Immunotherapy Intravesical

110

75.5% (83/110)

[95% Cl: bb% - 83%]

46.4% (51/110)

[95% CI: 37% - 56%)

4 1.Who (4 )

[95% Cl: 33% - 52%}

K-M: 64.2%

[95% Cl: 52% - 74%}

K-M: 60.1%

[95% CI: 48% - 70%)

96.4% at 24 month

89.2% at 12 month

81.3% at 24 month3

1 Day

SunRlSe-1

(Approved)

TAR-200

Gemcitabine via In-Dwelling Device

Transurethral Procedure

82.4% (70/83)

[95% CI: 73% - 90%)

K-M: 45.9% (39/83)

Not Reported

Observed: 52.9%

K-M: 56.2%

K-M: 51.8%

94.3%

86.6% at 12 month3

3.1 weeks

13%

QUILT 3.032

(Approved)

N-803 + BCG

IL-15 Superagonist

+ BCG combo

Intravesical

62.3% (48/77)

[95% Cl: 51% - 73%)

36.4% (28/77)4

24.7% (19/77)4

58%

40%

90%

59%3

Not Reported

Not reported; 16% SAE

NCTO2773849

(Approved)

Nadofaragene

Gene Therapy Secreting

IFN

Intravesical

51.0% (50/98)5

[95% Cl: 41% - 61%}

24.3% (25/103)

19.4% (20/103)

46%

Not Reported 94%

64% at 24-month Not Reported

KEYNOTE-057

(Approved)

Pembrolizumab

Checkpoint Inhibitor

Intravenous

40.6% (39/96)

[95% Cl: 31% - 51%}

18.8% (18/96)

9.4% (9/96)^

46%

Not Reported

89%

84%

Not Reported 13%

TR discontinuation

3.5% 7% 3%

11%

doi: Bio BCG age ; al ESMO Danesh Jo Oncology, JUIy 2025). CG On - SUO and NE AUA 2025; - ASCO

▪

Cretostimogene is Well Positioned in HR BCG-UR NMIBC with HG Ta/T1 with Potentially Best-in-Disease EFS Endpoint1

Trial (Status)

BOND-003 COHORT P

(Ph3 Ongoing)1

SunRISe-12

QUILT 3.0323

NCTO27738494•5

KEYNOTE-0576

Drug

Cretostimogene

TAR-200

N-803 + BCG

Nadofaragene

Pembrolizumab

Mechanism

Oncolytic Immunotherapy

Gemcitabine via In-Dwelling Device

IL-15 Superagonist

Gene Therapy Secreting IFN

Checkpoint Inhibitor

RoA

Intravesical

Transurethral Procedure

Intravesical

Intravenous

Efficacy Population

N=54

N=52

N=72

N=50

N=132

EFS/DFS/HG-RFS

3 month

95.7 [95% CI: 83.8, 98.9]

Not Reported

92.8% [95% CI]*

72.9 [95% CI: 58.2-84.7]

87.7 [95% CI: 80.7-92.3]

b month

84.6 [95% CI: 68.6, 92.9]

85.3 [95% CI: 71.6-92.7]

75.9% [95% CI]*

62.5 [95% CI: 47.4-76.0]

53.1 [95% CI: 44.1-61.2]

9 month

80.4 [95% Cl: 62.3, 90.4]

81.1 [95% CI: 66.7- 89.7]

Not Reported

58.3 [95% CI: 43.2-72.4]

Not Reported

12 month

NotYet Reached

74.3% [95% CI: 59.2-84.6]

55.4 [95% CI: 42.0-66.8]

43.8 [95% CI: 29.5-58.8]

43.5 [95% CI: 34.9-51.9]

24 month

Not Yet Reached

Not Reported

48.3 [95% CI: 34.5-60.7]

33.3 [95% CI: 20.4-48.4]

34.9 [95% CI: 26.4-43.4]

Safety

Grade 3+ TRAE

0 (0%)

13.5%

Not Reported

14%

TR discontinuation

0 (0%)

7.7%

11%

SAEs

0(0%)

5.8% including sepsis, spinal fracture (procedure

16%**

11%

13%

related), and UTI

+ BCG combo

1. SUO 2025 Annual Meeting; 2. JCO - https://doi.org/1 Phase lib SunRISe-1 study and SUO 2025 Annual Meeting presentation; 3. Chamie K, et al. NEJM Evid. 2023; 2(1):EVIDoa2200167 *estimated from subsequent landmark reports; **SAEs are combined across multiple cohorts as listed in package insert; 4. Boorjian S, et al. Lancet Oncology. 2021; 22(1):1 07-1 17. Narayan VM, et al. J Urol. 2024;212(1):74-86; 6. Necchi A, et al. Lancet Oncology. 2024; 25(6):720-730.

G 15

o o o o

▪ ▪ ▪

▪

▪ ▪

Cohort CX

CORE-008

Ph 2 Cretostimogene in Combination for High-Risk (HR) BCG-Exposed & BCG-Unresponsive NMIBC (Cohort CX) - First Results Expected 1H'2026

Population

Pathologically confirmed HR

BCG-exposed & BCG-UR

Persistent or recurrent HG Ta or CIS at first evaluation after adequate BCG dose

HG recurrence outside of BCG-UR window within 24 mos after last adequate BCG dose

HG recurrence within 24 mos after last inadequate BCG dose

Study Design / Regimen

Cohort CX (CIS-containing or HG

Ta/T1)

Arm 1 = cretostimogene + gemcitabine (concurrent)

Arm 2 = cretostimogene + gemcitabine (sequential)

Standard weekly x 6 induction, reinduction and weekly x 3 maintenance until Year 31

Additional Endpoints

CR at any time

CR at 1 2 months

DoR

PFS

CFS

HR = HG = LG = low DoR = of response. EFS = event free RFS = recurrence free PFS = free CFS = cystectomy free survival. undergo cytology and cystoscopy every 3 months for 2 years

1 Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders weekly x 3 every months Year 1, and every 6 months in Year 2 and Year

CISG 18

CORE-008

Phase 2 Cretostimogene Monotherapy for High-Risk (HR) BCG-Nai/'e and BCG-Exposed NMIBC (Cohort A and B)

Population

Cohort A

Pathologically confirmed HR

BCG-na"i"ve NMIBC

No prior treatment with BCG within past 24 months

Cohort B

Pathologically confirmed HR

BCG-exposed NMIBC

Recurrence within 24 months after last adequate BCG dose

Study Design / Regimen

Cohort A (HR BCG-na"i¥'e NMIBC)

CIS + HG Ta/T1 (n= 50)

HG Ta/T1 only (n= 75)

Standard weekly x 6 induction, reinduction and weekly x 3 maintenance until Year 31

Cohort B (HR BCG-exposed NMIBC)

CIS + HG Ta/T1 (n= 75)

HG Ta/T1 only (n= 75)

Standard dosing as above1

Additional Endpoints

Cohort A

DoR (in CIS)

EFS, LG-RFS, CFS

Cohort B

DoR (in CIS)

EFS, LG-RFS, CFS

HR =

HG = high

LG = low grade. DoR = duration of

EFS = event free survival. RFS = recurrence free

PFS = progression free survival. CFS = cystectomy free

Note:

undergo

cytology and cystoscopy every months for

2 years; mandatory, site-directed biopsy at month

Second course of weekly x 6 for non-responders at month Maintenance course for complete responders weekly x 3 every months Year and every 6 months in Year 2 and Year

2. CIS Rate) and HG Ta/T1

▪

Disclaimer

CG Oncology Inc. published this content on April 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 14, 2026 at 16:05 UTC.